Skip to content

iLink® for progressive keratoconus can make all the difference

iLink is the first and only FDA-approved corneal cross-linking procedure that slows or halts the progression of keratoconus (KC) and helps preserve vision. 

Get treatment that’s right for you

It’s important to meet with an eye doctor because the sooner a KC diagnosis is made—and a treatment plan is developed—the better the chances for preserving your vision. 

Find a Doctor

Keep in touch

Sign up today to receive valuable information and resources about iLink.

Sign up Now

Minimally invasive cross-linking

Corneal collagen cross-linking is a minimally invasive outpatient procedure to slow or halt the progression of keratoconus.

More about iLink

Still have questions about keratoconus?

Learn More
Find a Doctor

Important Safety Information

Ulcerative keratitis, a potentially serious eye infection, can occur. Your doctor should monitor defects in the outermost corneal layer of the eye for resolution.

The most common ocular side effect is haze. Other ocular side effects include inflammation, fine white lines, dry eye, disruption of surface cells, eye pain, light sensitivity, reduced sharpness of vision, and blurred vision. The risk information provided here is not comprehensive. To learn more, talk to your healthcare provider.

Go to Prescribing Info to obtain the FDA-approved product labeling.

You are encouraged to report all side effects to the FDA. Visit, or call 1-800-FDA-1088.

Approved Uses

Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) are used with the KXL® System in corneal cross-linking to treat eyes in which the cornea, the clear dome shaped surface that covers the front of the eye, has been weakened from the progression of the disease keratoconus or following refractive surgery, a method for correcting or improving your vision.

Tell your healthcare provider if you are pregnant or plan to become pregnant.